Biotech megarounds galore; New leaders at Novartis, Biogen; State of play for GLP-1 in NASH; Inside Illumina’s CEO search; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Despite a shorter week, we still saw biotech news come back in full force for September, particularly on the financing and people front — with Illumina finally making its CEO pick, in addition to Novartis and Biogen naming new leaders as part of a bigger vision. At Endpoints, we were excited to welcome Ayisha Sharma to the London team.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.